Drug intelligence / Profile preview

adalimumab biosimilar syn060

Development stage: Phase 1
Lead developer: Xingmeng Biopharmaceutical
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Subcutaneous

Overview

SYN060 is a biosimilar of adalimumab developed by Synermore Biologics. It is an anti-TNF monoclonal antibody designed to treat autoimmune diseases such as rheumatoid arthritis. Like the reference product (adalimumab, marketed as Humira), SYN060 acts as an immunosuppressant by inhibiting tumor necrosis factor alpha (TNF-α), a cytokine involved in systemic inflammation. The drug is being evaluated for its safety, pharmacokinetics, and immunogenicity compared to Humira in clinical trials[1][3][4].

Other names: adalimumab biosimilar SYN060

Targets

TNFA (Tumor necrosis factor alpha (soluble))

Beyond the preview

Go deeper on adalimumab biosimilar syn060.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on adalimumab biosimilar syn060.

Explore the full profile